-
Tytuł:
-
Can the triumph of mRNA vaccines against COVID-19 be extended to other viral infections of humans and domesticated animals?
-
Autorzy:
-
Sehrawat S; Department of Biological Sciences, Indian Institute of Science Education and Research Mohali, Sector 81, SAS Nagar Knowledge City, PO Manauli, Mohali 140306, Punjab, India. Electronic address: .
Osterrieder N; Institut für Virologie, Freie Universität Berlin, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany; Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, 5F, Block 1B, To Yuen Building, 31 To Yuen Street, Kowloon Tong, Hong Kong. Electronic address: .
Schmid DS; Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder, CO, USA. Electronic address: .
Rouse BT; College of Veterinary Medicine, University of Tennessee Knoxville, TN 37996-0845, USA. Electronic address: .
-
Źródło:
-
Microbes and infection [Microbes Infect] 2023 Jan-Feb; Vol. 25 (1-2), pp. 105078. Date of Electronic Publication: 2022 Nov 23.
-
Typ publikacji:
-
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Paris ; New York : Elsevier, c1999-
-
MeSH Terms:
-
COVID-19*/prevention & control
Virus Diseases*
Viral Vaccines*/genetics
Animals ; Humans ; COVID-19 Vaccines/genetics ; Animals, Domestic ; Pandemics/prevention & control ; RNA, Messenger/genetics ; mRNA Vaccines
-
Grant Information:
-
R01 EY005093 United States EY NEI NIH HHS; R21 AI142862 United States AI NIAID NIH HHS
-
Contributed Indexing:
-
Keywords: COVID-19; Human and animals; Immunopathology; Virus infections; mRNA vaccines
-
Substance Nomenclature:
-
0 (COVID-19 Vaccines)
0 (RNA, Messenger)
0 (mRNA Vaccines)
0 (Viral Vaccines)
-
Entry Date(s):
-
Date Created: 20221126 Date Completed: 20230110 Latest Revision: 20230203
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC9682868
-
DOI:
-
10.1016/j.micinf.2022.105078
-
PMID:
-
36435367
-
The unprecedented success of mRNA vaccines in managing the COVID-19 pandemic raises the prospect of applying the mRNA platform to other viral diseases of humans and domesticated animals, which may lead to more efficacious vaccines for some agents. We briefly discuss reasons why mRNA vaccines achieved such success against COVID-19 and indicate what other virus infections and disease conditions might also be ripe for control using mRNA vaccines. We also evaluate situations where mRNA could prove valuable to rebalance the status of immune responsiveness and achieve success as a therapeutic vaccine approach against infections that induce immunoinflammatory lesions.
Competing Interests: Declaration of competing interest The authors declare no conflict of financial interest.
(Copyright © 2022 Institut Pasteur. All rights reserved.)